The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Challenges in using CAR-T therapy & BTK inhibitors in patients with R/R MCL
Swetha Kambhampati, MD, City of Hope, Duarte, CA, discusses treatment challenges for patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Dr Kambhampati comments on the impact of BTK inhibitors and CAR-T therapy on the MCL treatment landscape, highlighting the need to optimize the sequencing of these therapies. Additionally, Dr. Kambhampati discusses how BTK inhibitors are moving to earlier lines of treatment and addresses the challenge of managing patients who relapse after receiving BTK inhibitors or CAR-T therapy. Finally, Dr. Kambhampati emphasizes the importance of understanding the impact of prior bendamustine induction therapy on subsequent treatment with CAR-T therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
